Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Gritstone bio, Inc. GRTS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
40/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$4.67
+14403.1%

Gritstone bio, Inc. (GRTS) is a Biotechnology company in the Healthcare sector, currently trading at $0.03. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is GRTS = $5 (+14403.1% upside).

Financials: revenue is $1M, +297.1%/yr average growth. Net income is $138M (loss), growing at -15%/yr. Net profit margin is -10405% (negative). Gross margin is -470.3% (+1625.5 pp trend).

Balance sheet: total debt is $105M against $52M equity (Debt-to-Equity (D/E) ratio 2.02, leveraged). Current ratio is 3.2 (strong liquidity). Debt-to-assets is 58.9%. Total assets: $178M.

Analyst outlook: 7 / 13 analysts rate GRTS as buy (54%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 15/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).

$4.67
▲ 14403.11% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Gritstone bio, Inc., the average price target is $4.67, with a high forecast of $6.00, and a low forecast of $3.00.
Highest Price Target
$6.00
Average Price Target
$4.67
Lowest Price Target
$3.00

GRTS SharesGrow Score Overview

47/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 15/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GRTS

✓
VALUE Pass
100/100
GRTS trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $5, implying +15428% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
GRTS: +297.1%/yr revenue is, -15%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet GRTS: Debt-to-Equity (D/E) ratio 2.02 (leveraged), Current ratio is 3.2 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
15/100
GRTS: Gross margin is -470.3% (+1625.5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 15/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 7 / 13 analysts rate GRTS as buy (54%). Analyst consensus target is $5 (+15428% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
GRTS: Net profit margin is -10405%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.03-3.17
Volume55.25M
Avg Volume (30D)17.01M
Market Cap$3.8M
Beta (1Y)0.50
Share Statistics
EPS (TTM)-1.20
Shares Outstanding$115.53M
IPO Date2018-09-28
Employees231
CEOAndrew R. Allen BCh, BM, MA, MRCP,
Financial Highlights & Ratios
Revenue (TTM)$1.33M
Gross Profit$-6.26M
EBITDA$-126.86M
Net Income$-138.49M
Operating Income$-154.63M
Total Cash$81.57M
Total Debt$104.78M
Net Debt$39.49M
Total Assets$177.77M
Price / Earnings (P/E)-0
Price / Sales (P/S)2.86
Analyst Forecast
1Y Price Target$5.00
Target High$6.00
Target Low$3.00
Upside+15,428.0%
Rating ConsensusBuy
Analysts Covering13
Buy 54% Hold 31% Sell 15%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS39868T1051

Price Chart

Track all markets on TradingView
GRTS
Gritstone bio, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.03 52WK RANGE 3.17

People Also View

BBIO
BBIO
BridgeBio Pharma, Inc.
$77.70
-0.30%
 IMGN
IMGN
ImmunoGen, Inc.
$31.24
+0.02%
 ERAS
ERAS
Erasca, Inc.
$18.20
+1.96%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 AUPH
AUPH
Aurinia Pharmaceuticals Inc.
$16.05
-0.12%
 CRVS
CRVS
Corvus Pharmaceuticals, Inc.
$15.11
-0.92%
 ANNX
ANNX
Annexon, Inc.
$6.35
+9.48%
 ALLO
ALLO
Allogene Therapeutics, Inc.
$2.17
-4.82%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message